TOXview: a novel graphical presentation of cancer treatment toxicity profiles

References

• Pinto E, Cavallin F, Saadeh LM, et al. Potential curability and perception of received information in esophageal cancer patients. Support Care Cancer. 2018;26:1807–1814.
   PubMed Web of Science ®Google Scholar
• Faller H, Koch U, Brähler E, et al. Satisfaction with information and unmet information needs in men and women with cancer. J Cancer Surviv. 2016;10:62–70.
   PubMed Web of Science ®Google Scholar
• Mendoza T. Time for better presentation and analysis of adverse events. Lancet Oncol. 2016;17:553–554.
   PubMed Web of Science ®Google Scholar
• Thanarajasingam G, Atherton PJ, Novotny PJ, et al. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016;17:663–670.
   PubMed Web of Science ®Google Scholar
• Yeh S-T. Clinical adverse events data analysis and visualization. The Pharmaceutical industry SAS users group conference proceedings; Denver, CO: GlaxoSmithKline, 2007. PO10.
   Google Scholar
• ter Veer E, Ngai LL, van Valkenhoef G, et al. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: a network meta-analysis. Sci Rep. 2017;7:3–10.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Wagner A, Syn N, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Data Syst Rev. 2017;8:CD004064. DOI: 10.1002/14651858.CD004064.pub4
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Van Cutsem E, Oh SC, et al. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016;27:673–679.
   PubMed Web of Science ®Google Scholar
• Veer ET, Mohammad NH, Van Valkenhoef G, et al. The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysis. J Natl Cancer Inst. 2016;108:1–13.
   Google Scholar
• Sivendran S, Latif A, McBride RB, et al. Adverse event reporting in cancer clinical trial publications. JCO. 2014;32:83–89.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Cochrane Collab. 2011. Available from: http://handbook.cochrane.org
   Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
   Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. R Found Stat Comput. 2018. Vienna, Austria. Available online at https://www.R-project.org/.
   Google Scholar
• Lu Y, Liu Z, Zhang J. S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study. J Chemother. 2014;26:159–164.
   PubMed Web of Science ®Google Scholar
• Yun J, Lee J, Park SH, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer. 2010;46:885–891.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26:149–156.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. JCO. 2005;23:494–501.
   PubMed Web of Science ®Google Scholar
• Tesselaar ME, Luelmo S, Polee M, et al. Randomized, phase II study comparing cisplatin and high-dose 5-fluorouracil/leucovorin with paclitaxel and high-dose 5-fluorouracil/leucovorin in patients with advanced gastric cancer and adenocarcinomas of the gastroesophageal junction. JCO. 2008;26:4567.
   Web of Science ®Google Scholar
• Tebbutt NC, Norman A, Cunningham D, et al. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002;13:1568–1575.
   PubMed Web of Science ®Google Scholar
• Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013;71:481–488.
   PubMed Web of Science ®Google Scholar
• Sugimoto N, Fujitani K, Imamura H, et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402). Anticancer Res. 2014;34:851–857.
   PubMed Web of Science ®Google Scholar
• Shirao K, Boku N, Yamada Y, et al. Randomized phase iii study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (jcog0106). Jpn J Clin Oncol. 2013;43:972–980.
   PubMed Web of Science ®Google Scholar
• Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168–176.
   PubMed Web of Science ®Google Scholar
• Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. JCO. 2015;33:3874–3879.
   PubMed Web of Science ®Google Scholar
• Sawaki a, Yamaguchi K, Nabeya Y, et al. 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial). Eur J Cancer Suppl. 2009;7:364.
   Web of Science ®Google Scholar
• Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016;27:2196–2203.
   PubMed Web of Science ®Google Scholar
• Ryu M-H, Park YI, Chung I-J, et al. Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study. JCO. 2016;34:4015.
   PubMed Web of Science ®Google Scholar
• Ryu MH, Baba E, Lee KH, et al. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015;26:2097–2101.
   PubMed Web of Science ®Google Scholar
• Roy A, Cunningham D, Hawkins R, et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. Br J Cancer. 2012;107:435–441.
   PubMed Web of Science ®Google Scholar
• Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss group for clinical cancer research. JCO. 2007;25:3217–3223.
   PubMed Web of Science ®Google Scholar
• Roth A, Kolaric K, Zupanc D, et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori. 1999;85:234–238.
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. JCO. 2002;20:1996–2004.
   PubMed Web of Science ®Google Scholar
• Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study. JCO. 2008;26:4512.
   Web of Science ®Google Scholar
• Richards D, Kocs DM, Spira AI, et al. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study. Eur J Cancer. 2013;49:2823–2831.
   PubMed Web of Science ®Google Scholar
• Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010;21:2213–2219.
   PubMed Web of Science ®Google Scholar
• Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol. 2004;15:1773–1781.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26:141–148.
   PubMed Web of Science ®Google Scholar
• Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17:225–229.
   PubMed Web of Science ®Google Scholar
• Ocvirk J, Reberšek M, Skof E, et al. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer. Am J Clin Oncol. 2012;35:237–241.
   PubMed Web of Science ®Google Scholar
• Ochenduszko S, Puskulluoglu M, Konopka K, et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Med Oncol. 2015;32:1–8.
   Web of Science ®Google Scholar
• Nishikawa K, Morita S, Matsui T, et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer. 2012;15:363–369.
   PubMed Web of Science ®Google Scholar
• Nio Y. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-Fluorouracil and cisplatin (FP) versus 5-Fluorouracil, cisplatin, and 4’-Epirubicin (FPEPIR). Anticancer Res. 1992;12:1983–1988.
   PubMed Web of Science ®Google Scholar
• Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14:72–80.
   PubMed Web of Science ®Google Scholar
• Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2010;21:71–77.
   PubMed Web of Science ®Google Scholar
• Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92:2122–2128.
   PubMed Web of Science ®Google Scholar
• Mochiki E, Ogata K, Ohno T, et al. Phase II multi-institutional prospective randomised trial comparing S-1paclitaxel with S-1cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer. 2012;107:31–36.
   PubMed Web of Science ®Google Scholar
• Lutz MP, Wilke H, Wagener DJT, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European organisation for research and treatment of cancer gastroi. JCO. 2007;25:2580–2585.
   PubMed Web of Science ®Google Scholar
• Wu D, Li X, Tong J, et al. S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer: a pilot randomized-controlled trial. Anticancer Drugs. 2015;26:774–778.
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–499.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Harry D, Chlebowski RT. 5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest New Drugs. 1994;12:57–63.
   PubMed Web of Science ®Google Scholar
• Li Y, Qiu M, Xu J, et al. S-1 plus Cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015;6; 35107–35115.
   Google Scholar
• Li X-D, Shen H, Jiang J-T, et al. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol. 2011;17:1082–1087.
   PubMed Web of Science ®Google Scholar
• Lee KH, Hyun MS, Kim H-K, et al. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res Treat. 2009;41:12.
   PubMed Web of Science ®Google Scholar
• Konings I, Van Der Gaast A, Van Der Wijk LJ, et al. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer. 2010;46:3200–3204.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.
   PubMed Web of Science ®Google Scholar
• Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008;99:584–590.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Tsuburaya A, Nishikawa K, et al. A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II). JCO. 2015;33:105.
   Web of Science ®Google Scholar
• Kim ST, Kang JH, Lee J, et al. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014;50:2822–2830.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. JCO. 1997;15:261–267.
   PubMed Web of Science ®Google Scholar
• Kim GM, Jeung H-C, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48:518–526.
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–673.
   PubMed Web of Science ®Google Scholar
• Jeung H-C, Rha SY, Im CK, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 2011;117:2050–2057.
   PubMed Web of Science ®Google Scholar
• Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15:1007–1018.
   PubMed Web of Science ®Google Scholar
• Ikeda R, Yoshida K, Satou Y, et al. Randomized phase II/III study of docetaxel/S-1 (DS-1) versus CDDP/5FU (FUP) in advanced or recurrent gastric cancer: updated phase II results. J Clin Oncol. 2009;27:4595.
   Google Scholar
• Icli F, Celik I, Aykan F, et al. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer. 1998;83:2475–2480.
   PubMed Web of Science ®Google Scholar
• Hwang IG, Ji JH, Kang JH, et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017;8:170–175.
   PubMed Web of Science ®Google Scholar
• Huang D, Ba Y, Xiong J, et al. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer. 2013;49:2995–3002.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial. JCO. 2016;34:443–451.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. JCO. 2011;29:3968–3976.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu R, Li J, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19:234–244.
   PubMed Web of Science ®Google Scholar
• Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive. JCO. 2014;32:3520–3526.
   PubMed Web of Science ®Google Scholar
• Fujitani K, Yang H-K, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–318.
   PubMed Web of Science ®Google Scholar
• Eatock MM, Tebbutt NC, Bampton CL, et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol. 2013;24:710–718.
   PubMed Web of Science ®Google Scholar
• Du F, Zheng Z, Shi S, et al. S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer. Medicine. 2015;94:e958.
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–1457.
   PubMed Web of Science ®Google Scholar
• Dai X, Zhang X, Wang C, et al. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients. Oncotarget. 2017;8:30495–30501.
   PubMedGoogle Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Chilvers CE, Amadori D, et al. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol Off J Eur Soc Med Oncol. 1994;5:33–36.
   PubMed Web of Science ®Google Scholar
• Colucci G, Giotta F, Maiello E, et al. Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Am J Clin Oncol Cancer Clin Trials. 1995;18:519–524.
   PubMed Web of Science ®Google Scholar
• Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil* Doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol. 2003;14:1258–1263.
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–489.
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. JCO. 1994;12:2687–2693.
   PubMed Web of Science ®Google Scholar
• Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie. JCO. 2004;22:4319–4328.
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–1069.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2016;19:919–926.
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49:835–842.
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–1442.
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Takahashi Y, Kimura Y, et al. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anticancer Drugs. 2011;22:576–583.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang ML, Zhou LY, et al. Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. Clin Transl Oncol. 2013;15:836–842.
   PubMed Web of Science ®Google Scholar
• Yoshino S, Nishikawa K, Morita S, et al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164–171.
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: atrial of the Europe. JCO. 2000;18:2648–2657.
   PubMed Web of Science ®Google Scholar
• Hironaka S, Sugimoto N, Yamaguchi K, et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:99–108.
   PubMed Web of Science ®Google Scholar
• Hall PS, Lord SR, Collinson M, et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017;116:472–478.
   PubMed Web of Science ®Google Scholar
• Kondo K, Sakamoto J, Nakazato H, et al. A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer. Oncol Rep. 2000;7:485–490.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Abramov M, Bondarenko I, et al. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017;28:2142–2148.
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E, Schuler MH, Zvirbule Z, et al. FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast. JCO. 2016;34:LBA4001–LBA4001.
   Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). JCO. 2003;21:54–59.
   PubMed Web of Science ®Google Scholar
• Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. JCO. 2008;26:4533.
   Web of Science ®Google Scholar
• Koizumi W, Yamaguchi K, Hosaka H, et al. Erratum: randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer (British Journal of Cancer (2013) 109 (2079-2086). Br J Cancer. 2014;111:2382.
   Web of Science ®Google Scholar
• Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. JCO. 2010;28:1547–1553.
   PubMed Web of Science ®Google Scholar
• Ajani J. A, Fodor MB, Tjulandin S. a, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. JCO. 2005;23:5660–5667.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. JCO. 2006;24:4991–4997.
   PubMed Web of Science ®Google Scholar
• Park SH, Nam E, Park J, et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol. 2007;19:729–733.
   PubMed Web of Science ®Google Scholar
• Zhang ZD, Kong Y, Yang W, et al. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. World J Surg Oncol. 2014;12:1–6.
   PubMed Web of Science ®Google Scholar
• Sivendran S, Galsky MD. Adverse event reporting in oncology clinical trials - lost in translation? Expert Opin Drug Saf. 2016;15:893–896.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen Q, Wang Q. The use of and adherence to CTCAE v3.0 in cancer clinical trial publications. Oncotarget. 2016;7:65577–65588.
   PubMedGoogle Scholar
• Schoen MW, Basch E, Hudson LL, et al. Software for administering the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events: usability study. JMIR Hum Factors. 2018;5:e10070.
   PubMedGoogle Scholar